Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LANADELUMAB Cause Oxygen saturation decreased? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Oxygen saturation decreased have been filed in association with LANADELUMAB (TAKHZYRO). This represents 0.4% of all adverse event reports for LANADELUMAB.

9
Reports of Oxygen saturation decreased with LANADELUMAB
0.4%
of all LANADELUMAB reports
2
Deaths
8
Hospitalizations

How Dangerous Is Oxygen saturation decreased From LANADELUMAB?

Of the 9 reports, 2 (22.2%) resulted in death, 8 (88.9%) required hospitalization, and 2 (22.2%) were considered life-threatening.

Is Oxygen saturation decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LANADELUMAB. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does LANADELUMAB Cause?

Hereditary angioedema (1,343) Product dose omission issue (555) Weight decreased (361) Weight increased (353) Inappropriate schedule of product administration (318) Product use issue (229) Covid-19 (225) Injection site pain (201) Insurance issue (172) Drug ineffective (142)

What Other Drugs Cause Oxygen saturation decreased?

TREPROSTINIL (3,865) RITUXIMAB (3,139) AMBRISENTAN (1,791) MACITENTAN (1,666) TOCILIZUMAB (1,501) METHOTREXATE (971) PREDNISONE (880) PACLITAXEL (833) ADALIMUMAB (813) SELEXIPAG (810)

Which LANADELUMAB Alternatives Have Lower Oxygen saturation decreased Risk?

LANADELUMAB vs LANADELUMAB-FLYO LANADELUMAB vs LANREOTIDE LANADELUMAB vs LANSOPRAZOLE LANADELUMAB vs LANTHANUM LANADELUMAB vs LANTUS

Related Pages

LANADELUMAB Full Profile All Oxygen saturation decreased Reports All Drugs Causing Oxygen saturation decreased LANADELUMAB Demographics